Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Savolitinib - AstraZeneca/HUTCHMED

X
Drug Profile

Savolitinib - AstraZeneca/HUTCHMED

Alternative Names: AZD-6094; HMP-504; HMPL-504; Orpathys; Volitinib; Voressa

Latest Information Update: 10 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hutchison MediPharma
  • Developer AstraZeneca; Hutchison MediPharma; HUTCHMED; National Cancer Institute (USA); Samsung Medical Center
  • Class Antineoplastics; Imidazoles; Pyrazines; Pyrazoles; Pyridines; Small molecules; Triazoles
  • Mechanism of Action Proto-oncogene protein c-met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • Phase III Renal cell carcinoma
  • Phase II Colorectal cancer; Gastric cancer; Oesophageal cancer; Prostate cancer
  • No development reported CNS cancer; Solid tumours

Most Recent Events

  • 10 Apr 2024 AstraZeneca plans a phase I trial in Healthy volunteers (In adults) in Sweden (PO) in April 2024 (NCT06348355) (EudraCT2023-508334-34-00)
  • 05 Apr 2024 AstraZeneca terminates a phase II trial for Non-small cell lung cancer (Combination therapy, Late-stage disease, Metastatic disease) in USA, India, Argentina, Taiwan, Thailand, Vietnam due to an additional ongoing SAVANNAH trial prior to April 2024 (PO) (NCT04606771)
  • 28 Mar 2024 National Medical Products Administration (NMPA) accepts the supplemental New Drug Application for savolitinib for Non-small cell lung cancer for review
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top